By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical today reported an 18 percent drop in total revenues for the second quarter as contract service fees and revenues from collaborative research arrangements took a 79 percent hit.

For the three months ended June 30, the company posted revenues of $2.3 million, down from $2.7 million a year ago, while contract service fees and collaborative research-based revenues dropped to $143,089 from $668,221 in Q2 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.